Aloradine - Pherin Pharmaceuticals

Drug Profile

Aloradine - Pherin Pharmaceuticals

Alternative Names: Aloradine IN; Aloradine NS; PH94B; PH94B NS

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pherin Pharmaceuticals
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Social phobia

Most Recent Events

  • 29 Jan 2018 Aloradine is still in phase III trials for Social phobia (Intranasal) in USA (Pherin Pharmaceuticals website, January 2018)
  • 18 Feb 2015 Pherin Pharmaceuticals has patent protection for Aloradine in USA, Australia, Canada, China, Denmark, France, Germany, Great Britain, Ireland, Italy, Japan, Mexico, Netherlands, South Korea, Spain, Sweden and Switzerland
  • 18 Feb 2015 Efficacy and adverse events data from a phase III trial in Social phobia released by Pherin Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top